Logo
x

Search

Subscribe Now

Horizon

Horizon Published (MIRROR) Trial Results of Krystexxa (pegloticase) + Methotrexate for Uncontrolled Gout in ACR Open Rheumatology

Horizon Published (MIRROR) Trial Results of Krystexxa (pegloticase) + Methotrexate for Uncontrolled Gout in ACR Open Rheumatology

  • July 7, 2023
Horizon Presents New P-IV Trial Results of Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease at ENDO 2023

Horizon Presents New P-IV Trial Results of Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease at ENDO 2023

  • June 20, 2023
Horizon Entered into a Multi-Year Scientific Collaboration with Johns Hopkins University School of Medicine to Advance Research in Autoimmunity and Inflammation

Horizon Entered into a Multi-Year Scientific Collaboration with Johns Hopkins University School of Medicine to Advance Research in...

  • November 17, 2022
Horizon Reports the Completion of Patients Enrollment of Tepezza (teprotumumab-trbw) in the P-III (OPTIC-J) Trial for the Treatment of Active Thyroid Eye Disease

Horizon Reports the Completion of Patients Enrollment of Tepezza (teprotumumab-trbw) in the P-III (OPTIC-J) Trial for the Treatmen...

  • November 17, 2022
Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

  • September 30, 2022
Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rheumatology

Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rhe...

  • September 15, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.